Trial Profile

Safety and Acceptability of Deferiprone Delayed Release Tablets in Patients With Systemic Iron Overload

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 21 Jun 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Deferiprone (Primary)
Indications Iron overload
Focus Adverse reactions
Acronyms TWICE
Sponsors ApoPharma

Most Recent Events

17 Jun 2021 Results presented at the 26th Congress of the European Haematology Association
21 Feb 2020 Status changed from active, no longer recruiting to completed.
06 Feb 2020 This trial has been completed in Greece, according to European Clinical Trials Database.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com